Home / Stocks / ILMN

Illumina (ILMN, Life Sciences Tools & Services) Stock Valuation & Fair Value Significantly overvalued

Illumina (ILMN, Life Sciences Tools & Services) trades at a blended P/E of 46.0, about 16% below its historical normal valuation, with a forward growth estimate of 14.0% and a PEG of 3.29. Analysts' one-year estimates have been hit 36% of the time.

DATA AS OF 2026-09-21
Blended P/E
46.0
Normal P/E
54.8
PEG
3.29
Fwd growth
14.0%
Div yield
0.0%
RSI (14)
71.3
Overbought
Technical context
  • Price $255.38 at the 2026-09-23 close, 15.3% above the 20-day average ($221.46) and 23.8% above the 50-day ($206.34).
  • RSI (14) at 71.3.
  • 52-week range $91.00 to $255.38: the price is at the high and 180.6% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ILMN is $202.65 across 20 analysts, 20.6% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 46.0 to 46.0 between 2026-09-19 and 2026-09-21, against a normal P/E of 54.8, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 46.0, Significantly overvalued (recalculated)2026-09-21: P/E 46.0, Significantly overvalued47.550.052.5Sep 19Sep 20Sep 21Normal P/E 54.8
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 46.0-16%Significantly overvalued
2026-09-21P/E 46.0-16%Significantly overvalued ← now

Frequently asked questions

Is Illumina stock overvalued?

At a blended P/E of 46.0 versus its historical normal P/E of 54.8, Illumina trades about 16% below its typical valuation, with a PEG of 3.29 on 14.0% forward growth. tickerseer currently rates it significantly overvalued.

What is Illumina's fair value and PEG?

Illumina trades at a blended P/E of 46.0 against a historical normal P/E of 54.8, a PEG of 3.29, and a forward growth estimate of 14.0%.

Has tickerseer's rating of Illumina changed?

tickerseer's rating has been significantly overvalued since 2026-09-19.

What is the analyst price target for Illumina?

The mean Wall Street price target for Illumina is $202.65 across 20 analysts, 20.6% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ILMN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.